Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
After announcing a data center lease agreement with artificial intelligence research company Anthropic and agreeing to sell its 50.1% equity in the Abernathy joint venture to Fluidstack, TeraWulf's stock surged significantly, rising by 14.3%.

After announcing a data center lease agreement with artificial intelligence research company Anthropic and agreeing to sell its 50.1% equity in the Abernathy joint venture to Fluidstack, TeraWulf's stock surged significantly, rising by 14.3%.

老虎证券老虎证券2026/07/06 13:53
Show original
This series of strategic initiatives marks that the company, focused on Bitcoin mining and high-performance computing infrastructure, is actively expanding its business footprint. The data center lease at Justified Data Campus will provide TeraWulf with a stable stream of hosting revenue and deepen its presence in the artificial intelligence computing sector. Meanwhile, the sale of the majority stake in the Abernathy joint venture will enable the company to optimize its asset structure and potentially reallocate resources to core growth areas. The market has responded positively, with a significant rise in the stock price reflecting investor recognition of the company’s new strategic direction. These transactions are expected to enhance TeraWulf’s financial flexibility and create new growth opportunities for it in the rapidly evolving digital infrastructure market.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46

SuperX AI Technology's stock price declined, falling more than 2.5% at one point.

智通财经•2026/10/08 16:11

BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars

Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)

路透社•2026/10/08 16:11